JP2014139214A - Mesenchymal stem cells and uses therefor - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide methods of: treating autoimmune diseases, allergic responses, cancer and inflammatory diseases; and promoting wound healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue.SOLUTION: Mesenchymal stem cells are administered in an effective amount to increase secretion of anti-inflammatory cytokines such as Interleukin-4 (IL-4) and Interleukin-10 (IL-10).

Description

  The present invention relates to mesenchymal stem cells. More particularly, the present invention relates to the promotion of angiogenesis in various tissues and organs, the treatment of autoimmune diseases, the treatment of allergic responses, the treatment of cancer, the treatment of inflammatory diseases and disorders, the promotion of wound healing, the treatment of inflammation And a novel use of mesenchymal stem cells including repair of epithelial injury.

  This invention was made with government support under Contract No. N66001-02-C-8068 by the Navy. The government has certain rights in the invention.

  This application claims priority based on provisional patent application No. 60 / 555,118, filed Mar. 22, 2004, the contents of which are hereby incorporated by reference in their entirety. 2005 This is a continuation-in-part application of Patent Application No. 11 / 080,298, filed on March 15, 2000.

Mesenchymal stem cells (MSCs) are pluripotent stem cells that can be easily differentiated into lineages including osteoblasts, muscle cells, chondrocytes, and adipocytes (Pittenger, et al., Science , Vol. 284, pg). 143 (1999); Haynesworth, et al., Bone , Vol. 13, pg. 69 (1992); Prockop, Science , Vol. 276, pg. 71 (1997)). In vitro studies have shown that MSCs are muscle (Wakitani, et al., Muscle Nerve , Vol. 18 ,, pg. 1417 (1995)), neuronal precursors (Woodbury, et al., J. Neurosci. Res. , Vol . 69, pg. 908 (2002); Sanchez-Ramos, et al., Exp. Neurol. , Vol. 171, pg. 109 (2001)), cardiomyocytes (Toma, et al., Circulation , Vol. 105, pg. 93 (2002); Fakuda, Artif. Organs , Vol. 25, pg. 187 (2001)), and possibly other types of cells have been demonstrated. Furthermore, MSC has been proven to be an effective feeder layer for expansion of hematopoietic stem cells and embryonic stem cells (Eaves, et al., Ann. NY Acad. Sci., Vol. 938, pg. 63 (2001). ); Wagers, et al., Gene Therapy , Vol. 9, pg. 606 (2002)). Recent studies using various animal models have demonstrated that MSCs are useful in the repair or regeneration of injured bone, cartilage, meniscus, or myocardial tissue (DeKok, et al., Clin Oral Implants Res. , Vol. 14, pg. 481 (2003)); Wu, et al., Transplantation , Vol. 75, pg. 679 (2003); Noel, et al., Curr. Opin. Investig. Drugs , Vol. 3, pg. 1000 (2002); Ballas, et al., J. Cell. Biochem. Suppl. , Vol. 38, pg. 20 (2002); Mackenzie, et al., Blood Cells Mol. Dis. , Vol. 27 (2002)). Some researchers have found osteogenesis imperfecta (Pereira, et al., Proc. Nat. Acad. Sci. , Vol. 95, pg. 1142 (1998)), Parkinson's disease (Schwartz, et al., Hum. Gene Ther. , Vol. 10, pg. 2539 (1999)), spinal cord injury (Chopp, et al., Neuroreport , Vol. 11, pg. 3001 (2000); Wu, et al., J. Neurosci. Res. , Vol. 72, pg. 393 (2003)), and heart disease (Tomita, et al., Circulation , Vol. 100, pg. 247 (1999). Shake, et al., Ann. Thorac. Surg. , Vol . 73, pg. 1919 (2002)), with promising results using MSC for transplantation in animal disease models. Importantly, promising results are also found in osteogenesis imperfecta (Horwitz, et al., Blood , Vol. 97, pg. 1227 (2001); Horowitz, et al. Proc. Nat. Acad. Sci., Vol . 99, pg. 8932 (2002)) and xenogeneic bone marrow transplantation (Frassoni, et al., Int. Society for Cell Therapy , SA006 (summary) (2002); Koc, et al., J. Clin. Oncol. , Vol . 18, pg. 307 (2000)) have also been reported in clinical trials of improved transplantation.

MSCs express major histocompatibility complex (MHC) class I antigens on their surface, but MHC class II (Le Blanc, et al., Exp. Hematol. , Vol. 31, pg. 890 (2003); Potian, et al., J. Immunol. , Vol. 171, pg. 3426 (2003)) and B7 are also CD40 costimulatory molecules (Majumdar, et al., J. Biomed. Sci. , Vol. 10, pg. 228). (2003)) does not express, suggesting that these cells have an immunogenic phenotype (Tse, et al., Transplantation , Vol. 75, pg. 389 (2003)). MSCs also inhibit the T cell proliferative response in an MHC-independent manner (Bartholomew, et al., Exp. Hematol. , Vol. 30, pg. 42 (2002); Devine, et al., Cancer J. , Vol. 7, pg. 576 (2001); DiNicola, et al., Blood , Vol. 99, pg. 3838 (2002)). These immunological properties of MSCs may improve transplantation and limit the ability of the recipient's immune system to recognize and reject allogeneic cells after transplantation. The ability of MSCs to modulate the immune response and support hematopoiesis, together with the ability to differentiate into appropriate types of cells under local stimulation, makes them preferred stem cells for cell transplantation studies (Majumdar, et al , Hematother. Stem Cell Res. , Vol. 9, pg. 841 (2000); Haynesworth, et al., J. Cell. Physiol. , Vol. 166, pg. 585 (1996)).

  Applicants examined the interaction between mesenchymal stem cells and isolated immune cell populations, including dendritic cells (DC1 and DC2), effector T cells (Th1 and Th2), and NK cells. Based on such interactions, Applicants have discovered that mesenchymal stem cells control the production of various factors that control several steps of the immune response process. That is, mesenchymal stem cells may be used to treat conditions and disorders involving the immune system, diseases, conditions and disorders involving inflammation, epithelial injury, or allergic responses. Such diseases, symptoms and disorders include, but are not limited to, autoimmune diseases, allergies, arthritis, inflamed wounds, alopecia areata (禿), periodontal diseases (including gingivitis and periodontitis), And other diseases, symptoms, or disorders that involve an immune response.

  Furthermore, mesenchymal stem cells express and secrete vascular endothelial growth factor, or VEGF, which promotes angiogenesis by stimulating the formation of new blood vessels. Mesenchymal stem cells also stimulate peripheral blood mononuclear cells (PBMC) to produce VEGF.

  In addition, mesenchymal stem cells stimulate dendritic cells to produce interferon-beta (IFN-β), which promotes tumor suppression and immunity against viral infection.

  In one aspect of the invention, a method of treating a disease selected from the group consisting of an animal autoimmune disease and graft-versus-host disease is provided. The method includes administering to the animal an amount of mesenchymal stem cells effective to treat the animal's disease.

While the scope of this aspect of the present invention is not limited to any theory, at least one mechanism by which mesenchymal stem cells suppress autoimmune disease and graft-versus-host disease may be regulatory T cells (T _reg cells) and / or This is believed to be due to the release of interleukin-10 (IL-10) from dendritic cells (DC).

  The autoimmune disease treated in the present invention is not particularly limited, but includes multiple sclerosis, type 1 diabetes, rheumatoid arthritis, uveitis, autoimmune thyroid disease, inflammatory bowel disease, scleroderma, Graves' disease , Lupus, Crohn's disease, autoimmune lymphoproliferative disease (ALPS), demyelinating disease, autoimmune encephalomyelitis, autoimmune gastritis (AIG), and autoimmune glomerulopathy. As described above, graft-versus-host disease is also treated. However, it is to be understood that the scope of the invention is not limited to the treatment of the specific diseases described herein.

  In certain embodiments, the animal to which mesenchymal stem cells are administered is a mammal. Mammals are primates, including human and non-human primates.

  In general, mesenchymal stem cell (MSC) therapy is based on the following order: collection of MSC-containing tissue, isolation and expansion of MSC, administration of MSC to animals (with or without biochemical or genetic manipulation).

  The mesenchymal stem cells to be administered can be a homogeneous composition or a mixed cell population enriched with MSCs. A uniform mesenchymal stem cell composition is obtained by culturing adherent bone marrow cells or periosteal cells, a mesenchymal stem cell composition is obtained by culturing adherent bone marrow cells or periosteal cells, Identified by specific cell surface markers identified using unique monoclonal antibodies. A method for obtaining a cell population enriched with mesenchymal stem cells is described, for example, in US Pat. No. 5,486,359. Other sources of mesenchymal stem cells include but are not limited to blood, skin, umbilical cord blood, muscle, fat, bone, and perichondrium.

  Mesenchymal stem cells are administered in various ways. Mesenchymal stem cells may be administered systemically, for example, by intravenous, intraarterial, or intraperitoneal administration.

  Mesenchymal stem cells may be derived from a range of sources including autologous, allogeneic, or xenogeneic.

Mesenchymal stem cells are administered in an amount effective to treat an animal autoimmune disease or graft-versus-host disease. Mesenchymal stem cells are administered in an amount of about 1 × 10 ⁵ cells / kg to about 1 × 10 ⁷ cells / kg. Mesenchymal stem cells In another embodiment is administered in an amount of about 1 × 10 ⁶ cells / kg to about 5 × 10 ⁶ cells / kg. The amount of mesenchymal stem cells administered depends on a variety of factors including the age, weight, sex, autoimmune disease being treated, and its extent and severity.

  Mesenchymal stem cells may be administered with a pharmaceutically acceptable carrier. For example, mesenchymal stem cells may be administered as a cell suspension in a pharmaceutically acceptable liquid medium or gel for injection or topical administration.

  In another aspect of the invention, a method of treating an inflammatory response in an animal is provided. The method includes administering to the animal an amount of mesenchymal stem cells effective to treat the animal's inflammatory response.

Although the scope of this aspect of the invention is not limited to any theory, it is believed that mesenchymal stem cells promote T cell maturation into regulatory T cells (T _reg cells), thus suppressing the inflammatory response. It is also believed that mesenchymal stem cells inhibit T helper 1 cells (Th1 cells), thereby reducing the expression of interferon-γ (IFN-γ) in certain inflammatory responses such as those associated with psoriasis.

  In certain embodiments, the inflammatory response to be treated is associated with psoriasis.

  In another embodiment, the mesenchymal stem cells are administered to the animal in contact with the microglia and / or astrocytes in the brain to reduce inflammation, thus the mesenchymal stem cells are treated with Alzheimer's disease, Parkinson Limits neurodegeneration caused by activated glial cells in diseases or disorders such as disease, stroke, or brain cell damage.

In yet another embodiment, the mesenchymal stem cells reduce inflammation, such as that caused by psoriasis, chronic dermatitis, and contact dermatitis, when the mesenchymal stem cells contact keratinocytes and Langerhans cells in the epidermis of the skin. Is administered to animals. Although the present invention is not limited to any theory, mesenchymal stem cells come into contact with keratinocytes and Langerhans cells in the epidermis to change the expression of T cell receptors and Langerhans cells in the epidermis, and thus tumor necrosis factor- It is thought to decrease the expression of alpha (TNF-α) and increase the population of regulatory T cells (T _reg cells).

In a further embodiment, the mesenchymal stem cell is an arthritis or arthritis-like condition including but not limited to osteoarthritis and rheumatoid arthritis, and other arthritic diseases described on the website www.arthritis.org/conditions/diseases. Used to reduce bone inflammation, as occurs. Although the scope of this embodiment of the invention is not limited to any theory, it is believed that mesenchymal stem cells inhibit interleukin-17 secretion by memory T cells in synovial fluid.

In another embodiment, mesenchymal stem cells are used to reduce inflammation in the gastrointestinal tract and liver in inflammatory bowel disease and chronic hepatitis, respectively. Although the scope of this embodiment of the invention is not limited to any theory, it is believed that mesenchymal stem cells promote increased secretion of interleukin-10 (IL-10) and the generation of regulatory T cells (T _reg cells). It is done.

  In another embodiment, mesenchymal stem cells are used to inhibit excessive activation of neutrophils and macrophages in pathological conditions such as sepsis and burns, surgery, and trauma including transplantation. While the scope of this embodiment of the invention is not limited to any theory, it is believed that mesenchymal stem cells promote secretion of suppressive cytokines such as IL-10 and inhibit macrophage migration inhibitory factor.

In another embodiment, the mesenchymal stem cells are immune, such as the eye, brain, spinal cord, pregnancy uterus and placenta, ovary, testis, adrenal cortex, liver, and hair follicle, including cornea, lens, pigment epithelial cells, and retina. Used to control inflammation of psychiatric privileged sites. Although the scope of this embodiment is not limited to any theory, it is believed that mesenchymal stem cells promote secretion of inhibitory cytokines such as IL-10 and generation of T _reg cells.

  In another embodiment, mesenchymal stem cells are used to treat tissue injury associated with dialysis and / or end stage renal disease (ESRD) of glomerulonephritis. Although the scope of this embodiment of the invention is not limited to any theory, it is believed that mesenchymal stem cells promote renal repair. Mesenchymal stem cells also express and secrete vascular endothelial growth factor (ie, VEGF), which is thought to stimulate new blood vessel formation and help repair damaged kidney tissue.

  In further embodiments, mesenchymal stem cells are used to control viral infections such as influenza, hepatitis C, herpes simplex virus, vaccinia virus infection, Epstein Barr virus. Although the scope of this embodiment is not limited to any theory, it is believed that mesenchymal stem cells promote the secretion of interferon-beta (IFN-β).

Mesenchymal stem cells In yet another embodiment is used to control parasitic infections such as leishmaniasis (Leishmania) infection or Helicobacter (Helicobacter) infections. Although the scope of this embodiment is not limited to any theory, it is believed that mesenchymal stem cells mediate the response by T helper 2 (Th2) cells and thus promote increased production of immunoglobulin E (IgE) by β cells. .

  However, it should be understood that this aspect of the invention is not limited to the treatment of specific inflammatory responses.

  Mesenchymal stem cells are administered to mammals including human and non-human primates as described above.

  Mesenchymal stem cells are also administered systemically as described above. Alternatively, in the case of osteoarthritis or rheumatoid arthritis, mesenchymal stem cells are administered directly to the arthritic joint.

Mesenchymal stem cells are administered in an amount effective to treat the inflammatory response of the animal. Mesenchymal stem cells are administered in an amount of about 1 × 10 ⁵ cells / kg to about 1 × 10 ⁷ cells / kg. Mesenchymal stem cells In another embodiment is administered in an amount of about 1 × 10 ⁶ cells / kg to about 5 × 10 ⁶ cells / kg. The exact dose of mesenchymal stem cells administered depends on a variety of factors including the age, weight, sex, inflammatory response to be treated, and its extent and severity.

  As described above, mesenchymal stem cells are administered with a pharmaceutically acceptable carrier.

  In another aspect of the invention, a method of treating animal inflammation and / or repairing epithelial injury is provided. The method includes administering to the animal an amount of mesenchymal stem cells effective to treat the animal's inflammation and / or epithelial injury.

  Although the scope of this aspect of the present invention is not limited to any theory, mesenchymal stem cells have reduced secretion of pro-inflammatory cytokines TNF-α and interferon-γ by T cells and anti-inflammatory properties by T cells. It is thought to cause an increase in secretion of cytokines interleukin-10 (IL-10) and interleukin-4 (IL-4). In addition, mesenchymal stem cells are thought to cause a decrease in interferon-γ secretion by natural killer (NK) cells.

  Inflammation and / or epithelial injury treated in this aspect of the invention includes, but is not limited to, autoimmune diseases, transplant rejection, burns, cuts, lacerations, skin ulceration and diabetic ulceration. There is inflammation and / or epithelial damage caused by various diseases and disorders that are not.

  In certain embodiments, the mesenchymal stem cells are rheumatoid arthritis, Crohn's disease, type 1 diabetes, multiple sclerosis, scleroderma, Graves' disease, lupus, inflammatory bowel disease, autoimmune gastritis (AIG), and autoimmunity. Administered to animals to repair epithelial damage caused by autoimmune diseases, including but not limited to glomerular diseases. Mesenchymal stem cells also repair epithelial damage caused by graft-versus-host disease (GVHD).

  This aspect of the invention relates to the repair of epithelial damage caused by graft-versus-host disease, and more particularly severe transplants including grade III and IV graft-versus-host diseases that affect the skin and / or gastrointestinal system. Applies to repair of epithelial damage caused by unilateral host disease. Applicants are particularly interested in the administration of mesenchymal stem cells when they are administered to patients suffering from severe graft-versus-host disease, especially grade III and IV gastrointestinal graft-versus-host disease. Of the skin and / or ulcerated small intestine epithelium.

  In another embodiment, mesenchymal stem cells are administered to an animal to repair epithelial damage to the transplanted organ or tissue, including but not limited to kidney, heart, and lung, caused by rejection of the transplanted organ or tissue. The

  In yet another embodiment, mesenchymal stem cells are administered to an animal to repair epithelial damage caused by ulceration, including burns, cuts, lacerations, skin ulceration and diabetic ulceration.

  Mesenchymal stem cells are administered to mammals including human and non-human primates as described above.

  Mesenchymal stem cells are also administered systemically as described above.

Mesenchymal stem cells are administered in an amount effective to repair the epithelial injury of the animal. Mesenchymal stem cells are administered in an amount of about 1 × 10 ⁵ cells / kg to about 1 × 10 ⁷ cells / kg. Mesenchymal stem cells In another embodiment is administered in an amount of about 1 × 10 ⁶ cells / kg to about 5 × 10 ⁶ cells / kg. The exact dose of mesenchymal stem cells administered will depend on a variety of factors including the age, weight, sex, type of epithelial injury being repaired, and its extent and severity.

  In another aspect of the invention, a method of treating animal cancer is provided. The method includes administering to the animal an amount of mesenchymal stem cells effective to treat the animal's cancer.

  While the scope of this aspect of the invention is not limited to any theory, it is believed that mesenchymal stem cells interact with dendritic cells to secrete IFN-β, which in turn acts as a tumor suppressor. Cancers to be treated include but are not limited to hepatocellular carcinoma, cervical cancer, pancreatic cancer, prostate cancer, fibrosarcoma, medulloblastoma, and astrocytoma. However, it should be understood that the scope of the present invention is not limited to a particular type of cancer.

  The animals are mammals including humans and non-human primates as described above.

Mesenchymal stem cells are administered in an amount effective to treat animal cancer. Generally, mesenchymal stem cells are administered in an amount of about 1 × 10 ⁵ cells / kg to about 1 × 10 ⁷ cells / kg. Mesenchymal stem cells In another embodiment is administered in an amount of about 1 × 10 ⁶ cells / kg to about 5 × 10 ⁶ cells / kg. The exact dose of mesenchymal stem cells administered will depend on a variety of factors including the age, weight, sex, type of cancer being treated, and its extent and severity.

  As described above, mesenchymal stem cells are administered with a pharmaceutically acceptable carrier and administered systemically. Alternatively, mesenchymal stem cells are administered directly to the cancer being treated.

  In another aspect of the invention, a method of treating an animal allergic disease or disorder is provided. The method comprises administering to the animal an amount of mesenchymal stem cells effective to treat the animal's allergic disease or disorder.

  While the scope of this aspect of the invention is not limited to any theory, it is believed that when mesenchymal stem cells are administered after an acute allergic response, they provide mast cell activation and inhibition of degranulation. Mesenchymal stem cells also down-regulate basophil activation, cytokines such as TNF-α, chemokines such as interleukin-8, monocyte chemoattractant protein (ie MCP-1), lipid mediators such as leukotrienes It is thought to inhibit major mediators such as histamine, heparin, chondroitin sulfate, and cathepsin.

  Allergic diseases or disorders to be treated include but are not limited to asthma, allergic rhinitis, atopic dermatitis, and contact dermatitis. However, it should be understood that the scope of the present invention is not limited to a particular allergic disease or disorder.

Mesenchymal stem cells are administered in an amount effective to treat an animal allergic disease or disorder. The animal may be a mammal. The mammal may be a primate, including human and non-human primates. Generally, mesenchymal stem cells are administered in an amount of about 1 × 10 ⁵ cells / kg to about 1 × 10 ⁷ cells / kg. Mesenchymal stem cells In another embodiment is administered in an amount of about 1 × 10 ⁶ cells / kg to about 5 × 10 ⁶ cells / kg. The exact dose of mesenchymal stem cells administered will depend on a variety of factors including the age, weight, sex, allergic disease or disorder being treated, and its extent and severity.

  As described above, mesenchymal stem cells are administered with a pharmaceutically acceptable carrier. Mesenchymal stem cells are administered systemically, for example intravenously or intraarterially.

  In a further aspect of the invention, a method is provided for promoting wound healing in an animal. The method includes administering to the animal an amount of mesenchymal stem cells effective to promote wound healing in the animal.

Although the scope of the present invention is not limited to any theory, as described above, mesenchymal stem cells cause T _reg cells and dendritic cells to release interleukin-1-10 (IL-10). IL-10 limits or inhibits wound inflammation and thus promotes wound healing.

In addition, mesenchymal stem cells promote wound healing and fracture healing by inducing secretory factors by other types of cells. For example, mesenchymal stem cells are prostaglandin E ₂ (PGE ₂ ) -mediated release of vascular endothelial growth factor (VEGF) by peripheral blood mononuclear cells (PBMC), as well as growth hormone, insulin, insulin-like growth factor 1 (IGF− 1) Induces PGE ₂ -mediated release of insulin-like growth factor binding protein-3 (IGFBP-3) and endothelin-1.

  Healing wounds include, but are not limited to, those resulting from cuts, lacerations, burns, and skin ulceration.

Mesenchymal stem cells are administered to the animal in an amount effective to promote animal wound healing. The animal may be a mammal, and the mammal may be a primate, including human and non-human primates. Generally, mesenchymal stem cells are administered in an amount of about 1 × 10 ⁵ cells / kg to about 1 × 10 ⁷ cells / kg. Mesenchymal stem cells In another embodiment is administered in an amount of about 1 × 10 ⁶ cells / kg to about 5 × 10 ⁶ cells / kg. The exact dose of mesenchymal stem cells administered depends on a variety of factors including the patient's age, weight, sex, the wound being treated, and its extent and severity.

  As described above, mesenchymal stem cells are administered with a pharmaceutically acceptable carrier. Mesenchymal stem cells are administered systemically as described above. Alternatively, mesenchymal stem cells are administered directly to the wound with a liquid on a bandage or reservoir containing mesenchymal stem cells.

  In yet another aspect of the invention, a method for treating or preventing fibrosis in an animal is provided. The method includes administering to the animal an amount of mesenchymal stem cells effective to treat or prevent fibrosis in the animal.

  Mesenchymal stem cells can be any type of fibrosis in animals, including but not limited to cirrhosis, renal fibrosis associated with end stage renal disease, and pulmonary fibrosis, adult respiratory distress syndrome (ARDS) and Administered to animals to treat or prevent pulmonary fibrosis, including but not limited to chronic obstructive pulmonary disease (COPD). It should be understood that the scope of the present invention is not limited to a particular type of fibrosis.

Mesenchymal stem cells are administered to the animal in an amount effective to treat or prevent fibrosis in the animal. The animal may be a mammal, and the mammal may be a primate, including human and non-human primates. Generally, mesenchymal stem cells are administered in an amount of about 1 × 10 ⁵ cells / kg to about 1 × 10 ⁷ cells / kg. Mesenchymal stem cells In another embodiment is administered in an amount of about 1 × 10 ⁶ cells / kg to about 5 × 10 ⁶ cells / kg. The exact dose of mesenchymal stem cells administered will depend on a variety of factors including the age, weight, sex, and extent and severity of fibrosis to be treated or prevented.

  Mesenchymal stem cells are administered with a pharmaceutically acceptable carrier as described above. Mesenchymal stem cells are administered systemically as described above.

  Another object of the present invention is to promote angiogenesis of an animal tissue or organ, where the tissue or organ requires angiogenesis.

  In a further aspect of the invention, a method for promoting angiogenesis in an animal organ or tissue is provided. The method includes administering to the animal an amount of mesenchymal stem cells effective to promote angiogenesis of the organ or tissue of the animal.

  Angiogenesis is the formation of new blood vessels from an existing microvascular bed.

  Induction of angiogenesis is used to treat coronary and peripheral arterial insufficiency and may be a non-invasive and therapeutic approach for the treatment of coronary artery disease, ischemic heart disease, and peripheral blood artery disease. Angiogenesis plays a role in the treatment of diseases and disorders of tissues and organs other than the heart, and in the growth and / or maintenance of organs other than the heart. Angiogenesis plays a role in the treatment of internal and external wounds and skin ulcers. Angiogenesis also plays a role in embryo implantation, placental growth, and embryonic vessel growth. Angiogenesis is also essential for the connection between cartilage resorption and bone formation and is essential for correct growth plate morphogenesis.

  In addition, angiogenesis is necessary for the successful construction and maintenance of highly metabolic organs, such as the liver, that require the dense vascular network necessary to provide sufficient nutrient and gas transport.

  Mesenchymal stem cells can be administered to tissues or organs in need of angiogenesis by various methods. Mesenchymal stem cells are administered systemically, for example, by intravenous, intraarterial, or intraperitoneal administration, or mesenchymal stem cells, for example, by direct administration to a tissue or organ in need of angiogenesis. Administered directly to the necessary tissue or organ.

  Mesenchymal stem cells may be derived from a range of sources including autologous, allogeneic, or xenogeneic.

  While the scope of the present invention is not limited to any theory, mesenchymal stem cells, when administered to animals, stimulate peripheral blood mononuclear cells (PBMC) to produce vascular endothelial growth factor (ie, VEGF), which It is thought to stimulate the formation of new blood vessels.

  In certain embodiments, the animal is a mammal. The mammal may be a primate, including human and non-human primates.

  The mesenchymal stem cells of the present invention are used for the treatment, alleviation or prevention of diseases or disorders that can be alleviated, treated or prevented through angiogenesis. For example, mesenchymal stem cells are administered to animals to treat the extremities (ie arms, legs, hands, and feet), and the occluded arteries in the neck or various organs. For example, mesenchymal stem cells are used to treat occluded arteries that meet the needs of the brain, and thus treat or prevent stroke. Mesenchymal stem cells are also used to treat embryonic and postnatal corneal blood vessels and provide glomerular structure formation. In another embodiment, the mesenchymal stem cell is a foot, hand, leg, or arm that includes, but is not limited to, treatment of internal and external wounds, and skin ulcers caused by diseases such as diabetes and sickle cell anemia. Used to treat skin ulcers.

  Furthermore, since angiogenesis is involved in embryo implantation and placenta formation, mesenchymal stem cells are used to promote embryo implantation and prevent miscarriage.

  In addition, mesenchymal stem cells are administered to animals in the womb, including humans, to promote blood vessel growth in the animals in the womb.

  In another embodiment, mesenchymal stem cells are administered to postnatal or prenatal animals to promote cartilage resorption and bone formation and promote correct growth plate morphogenesis.

Mesenchymal stem cells are administered in an amount effective to promote angiogenesis in the animal. Mesenchymal stem cells are administered in an amount of about 1 × 10 ⁵ cells / kg to about 1 × 10 ⁷ cells / kg. Mesenchymal stem cells In another embodiment is administered in an amount of about 1 × 10 ⁶ cells / kg to about 5 × 10 ⁶ cells / kg. The amount of mesenchymal stem cells administered depends on a variety of factors including the age, weight, sex, treatment, alleviation or prevention of the disease or disorder of the patient and its extent and severity.

  Mesenchymal stem cells may be administered with a pharmaceutically acceptable carrier. For example, mesenchymal stem cells may be administered as a cell suspension in a pharmaceutically acceptable liquid medium for injection. Injection may be local, ie directly into the tissue or organ in need of angiogenesis, or systemic.

  Mesenchymal stem cells may be genetically engineered with one or more polynucleotides encoding a therapeutic agent. The polynucleotide is provided to mesenchymal stem cells via an appropriate expression vehicle. Expression vehicles used to genetically manipulate mesenchymal stem cells include, but are not limited to, retroviral vectors, adenoviral vectors, and adeno-associated viral vectors.

  The selection of an appropriate polynucleotide encoding a therapeutic agent depends on a variety of factors including the disease or disorder being treated and its extent and severity. Polynucleotides encoding therapeutic agents and suitable expression vehicles are further described in US Pat. No. 6,355,239.

  Mesenchymal stem cells, when used in the above treatment, include other therapeutic agents known to those skilled in the art, including but not limited to agents such as growth factors, cytokines, anti-inflammatory agents, and cells other than mesenchymal stem cells Used in combination with, for example, dendritic cells, or administered in combination with a soluble carrier for the cells, such as hyaluronic acid, or a suitable solid matrix such as collagen, gelatin, or other biocompatible polymers .

  The methods described herein are performed in many ways and with various modifications and substitutions known in the art. It should be understood that the theory proposed for the mode of action or interaction between cell types is in no way limiting on the present invention and is provided so that the method of the present invention can be better understood.

  The present invention will be described with reference to the drawings.

  FIG. MSCs regulate dendritic cell function. (A) Flow cytometric analysis of mature monocyte DC1 cells using antibodies against HLA-DR and CD11c, and plasmacytoid DC2 cell flow sites using antibodies against HLA-DR and CD123 (IL-3 receptor) Metric analysis. (Dashed line): isotype control; (solid line): FITC / PE-conjugated antibody. (B) MSC inhibits TNF-α secretion (first y-axis) from activated DC1 and DC2, respectively, and increases IL-10 secretion (second y-axis). (C) MSCs cultured in mature DC1 cells inhibit IFN-γ secretion (first y-axis) by T cells and increase IL-4 levels (second y-axis) compared to MSC or DC alone. Decreased production of pro-inflammatory IFN-γ and increased production of anti-inflammatory IL-4 in the presence of MSC indicated a shift of the T cell population to an anti-inflammatory phenotype.

FIG. MSCs inhibit pro-inflammatory effector T cell function. (A) Number of T _Reg cells by staining PBMC or non-adherent fraction in MSC + PBMC cultures (MSC + PBMC) using FITC-conjugated CD4 (x-axis) and PE-conjugated CD25 (y-axis) antibodies (%) Flow cytometric analysis. The gate is based on the isotype control antibody as background. The graph is representative of 5 independent experiments. (B) In cell culture supernatant, T _H 1 cells generated in the presence of MSC secrete low levels of IFN-γ (first y axis), and T _H 2 cells generated in the presence of MSC increase. An amount of IL-4 (second y-axis) was secreted. (C) MSC inhibits IFN-γ secretion from purified NK cells cultured in 24-well plates for 0, 24, or 48 hours. Data shown is the mean ± SD cytokine secretion of one experiment and is representative of three independent experiments.

FIG. MSC increases the number of T _reg cell populations and GITR expression. (A) CD4 ⁺ CD25 ⁺ T _reg cell populations were isolated from PBMC or MSC + PBMC (MSC to PBMC ratio 1:10) cultures (cultured for 3 days without further stimulation) using a two-step magnetic isolation method. Released. These cells are irradiated (to prevent further proliferation) and used as stimulator cells in a mixed lymphocyte reaction (MLR), where the responder cells are plant hemagglutinin (PHA) (2.5 mg / ml) Allogeneic PBMC in the presence of (stimulating cell to responding cell ratio 1: 100). The cells were cultured for 48 hours, then ³ H thymidine was added and 24 hours later, the incorporated radioactivity was counted. The results showed that the T _reg population generated in the presence of MSC (lane 3) is functionally equivalent to the T _reg cells generated in the absence of MSC (lane 2). (B) PBMCs were cultured for 3 days in the absence (upper plot) or presence (lower plot) of MSC (MSC to PBMC ratio 1:10), then the non-adherent fraction was collected and FITC Immunostaining was performed with labeled GITR and PE-labeled CD4. The results show more than a 2-fold increase in GITR expression in cells cultured in the presence of MSC.

FIG. The MSC of PGE ₂ produced, MSC immunomodulatory effects when blocking PGE ₂ is reversed. (A) PGE ₂ secretion (mean ± SD) in culture supernatants obtained from MSCs cultured in the presence or absence of various concentrations of PGE ₂ blockers NS-398 or indomethacin (Indometh.). The inhibitor concentration is μM, and the data shown are values obtained after 24 hours of culture. (B) COX-1 and COX-2 expression in MSC and PBMC using real-time RT-PCR. MSCs expressed significantly higher levels of COX-2 compared to PBMC, and when MSCs were cultured in the presence of PBMC, there was a more than 3-fold increase in COX-2 expression in MSCs. Representative data from 1-3 independent experiments are shown. MSC + PBMC cultures were prepared in transwell chamber plates, where MSCs were seeded in the lower chamber and PBMCs were seeded in the upper chamber. (C) Presence of indomethacin (Ind.) Or NS-398, PGE ₂ blockers, indicates TNF-α secretion from activated DCs (white bars) and T _H 1 cells (hatched bars) compared to controls. Increases IFN-γ secretion from Data were calculated as% change from cultures produced in the absence of MSC and PGE ₂ inhibitor. (D) The presence of PGE ₂ blockers indomethacin (Indo) or NS-398 in MSC-PBMC co-culture (1:10) reverses the MSC antiproliferative effect on PHA-treated PBMC. The data shown is from one experiment and is representative of three independent experiments.

FIG. Constitutive MSC cytokine secretion is elevated in the presence of allogeneic PBMC. Cytokine IL in the culture supernatant of MSC cultured for 24 hours in the presence (diagonal line) or absence (white bar) (MSC to PBMC ratio 1:10) using human MSCs already characterized -6 and VEGF, were analyzed the levels of lipid mediators PGE _2, and matrix metalloproteinase 1 (pro-MMP-1) . The MSC IL-6, VEGF, and produce PGE ₂ constitutively, elevated levels of these factors in the co-culture with PBMC, therefore the MSC to play a role in the regulation of immune function in inflammatory conditions Suggest.

FIG. MSCs inhibit mitogen-induced T cell proliferation in a dose-dependent manner. Increasing numbers of allogeneic PBMCs were incubated with a fixed number of MSCs (2,000 cells / well) seeded in 96-well plates in the presence or absence of PHA (2.5 mg / ml), and ³ H Thymidine incorporation was measured (counts per minute, cpm). There was a dose-dependent inhibition of proliferation of PHA-treated PBMC in the presence of MSC. A typical result from one of three independent experiments is shown. Similar results were reported by LeBlanc, et al., Scand J. Immunol. , Vol. 57, pg. 11 (2003).

FIG. Schematic diagram of proposed MSC mechanism of action MSCs are cells from both the innate (DC pathway 2-4; and NK pathway 6) immune system and the adaptive (T pathway 1 and 5, and B pathway 7) immune system. Mediates immunomodulatory effects by affecting In response to invading pathogens, immature DCs migrate to invading sites, mature, stimulate untreated T cells (by antigen-specific and costimulatory signals), and protective effector T cells (cellular T acquire the ability to become _H 1 or humoral T _H 2 immune). During MSC-DC interactions, MSCs either by direct cell-cell contact or by secreted factors limit the ability of DCs to initiate a cellular response (path 2) or a humoral response (path 4 By altering the outcome of the immune response. Also, when mature effector T cells are present, MSCs interact with them to shift the balance of the T _H 1 (path 1) response towards the TH 2 response (path 5), possibly of IgE-producing B cell activity (path 7). Toward an increase, which is a favorable outcome for the suppression of GvHD and autoimmune disease symptoms. MSCs become a tolerant phenotype by virtue of their ability to increase the generation of the T _Reg population (path 3) and help the recipient host by alleviating bystander inflammation in the local microenvironment. The dotted line (----) is the proposed mechanism.

  The invention is illustrated by the following examples; however, the scope of the invention is in no way limited by these.

Example 1

Materials and methods

Culture of human MSCs Human MSCs were cultured as described in Pittenger et al., Science , Vol. 284, pg. 143 (1999). That is, bone marrow samples were collected from the iliac crests of anonymous donors after informed consent by Poietics Technologies, Div of Cambrex Biosciences. Complete Dulbecco's Modified Eagle Medium-Low Glucose (Life Technologies, Carlsbad, California) containing 1% antibiotic-antifungal solution (Invitrogen, Carlsbad, California) and 10% fetal bovine serum (FBS, JRH BioSciences, Lenexa, Kansas) MSCs were cultured in MSCs grew as adherent monolayers and were stripped using trypsin / EDTA (0.05% trypsin at 37 ° C. for 3 minutes). All MSCs used were already characterized for pluripotency and retained the ability to differentiate into mesenchymal lineages (chondrogenic, adipogenic, and osteogenic) (Pittenger, et al., Science , Vol. 284, pg. 143 (1999)).

Dendritic cell isolation Peripheral blood mononuclear cells (PBMC) were obtained from Poietics Technologies, Div of Cambrex Biosciences (Walkersville, MD). Monocyte lineage (CD1c ⁺ ) dendritic cell (DC) precursors were analyzed using a two-step magnetic separation method according to Dzionek, et. Al., J. Immunol. , Vol. 165, pg. 6037 (2000). And positively selected from PBMC. That is, CD1c-expressing B cells were magnetically depleted of CD19 ⁺ cells using magnetic beads, and then the B cell depleted fraction was labeled with biotin-labeled CD1c (BDCA1 ⁺ ) and anti-biotin antibody, and the manufacturer ( These were separated from the unlabeled cell fraction using a magnetic column according to the instructions of Miltenyi Biotech, Auburn, California). Plasma cell-like lineage DC precursors were isolated from PBMC by immuno-magnetic classification of positively labeled antibody-coated cells (BDCA2 ⁺ ) (Miltenyi Biotech, Auburn, California).

MSC-DC cultures In most experiments, human MSCs and DCs were cultured in the same number for various times and cell culture supernatants were collected and stored at -80 ° C until further evaluation. In selected experiments, MSCs were cultured with mature DC1 or DC2 cells (1: 1 MSC: DC ratio) for 3 days and then combined cultures (MSC and DC) were irradiated to stop further growth. . Next, untreated allogeneic T cells (CD4 ⁺ , CD45RA ⁺ ) purified with antibodies were added to the irradiated MSC / DC and cultured for an additional 6 days. The non-adherent cell fraction (purified T cells) is then collected from the culture, washed twice, restimulated with PHA for another 24 hours, and then the cell culture supernatant is collected and the isolated IFN-γ And IL-4 were analyzed by ELISA.

Isolation of NK cells Biotin-conjugated monoclonal antibody cocktail (anti-CD3, -CD14, -CD19, -CD36, and anti-IgE antibody) as a primary reagent, and anti-biotin monoclonal antibody bound to microbeads as a secondary labeling reagent As a result, a purified population of NK cells was obtained by depleting magnetically labeled non-NK cells. Magnetically labeled non-NK cells were retained in a MACS (Miltenyi Biotech, Auburn, California) column in a magnetic field, and NK cells passed through and collected.

It was isolated T _Reg cell populations by using the isolated two-step method for isolating T _Reg cell population. First, non-CD4 ⁺ T cells were indirectly magnetically labeled using a cocktail of biotin-labeled antibodies and anti-biotin microbeads. The labeled cells were then separated and depleted with a MACS column (Miltenyi Biotech, Auburn, California). CD4 ⁺ CD25 ⁺ cells were then directly labeled with CD25 microbeads and isolated from pre-enriched CD4 ⁺ T cell fractions by positive selection. Magnetically labeled CD4 ⁺ CD25 ⁺ cells were retained on the column and eluted after removal of the column from the magnetic field.

To investigate whether the increase in the CD4 ⁺ CD25 ⁺ population generated in the presence of MSC is naturally inhibitory, the CD4 ⁺ CD25 ⁺ T _reg cell population was _analyzed using PBMC using a two-step magnetic isolation method. Alternatively, isolated from MSC + PBMC (MSC to PBMC ratio is 1:10) culture (cultured for 3 days without further stimulation). These cells are irradiated to prevent further growth and used as stimulator cells in a mixed lymphocyte reaction (MLR), where responder cells are allogeneic PBMCs (2.5 μg / ml) in the presence of PHA (2.5 μg / ml). The ratio of stimulator cells to responder cells was 1: 100). Incubate for 48 hours. ³ H thymidine was then added. The radioactivity incorporated after 24 hours was measured.

  PBMCs are cultured in the absence or presence of MSC (MSC to PBMC ratio is 1:10), then the non-adhesive fraction is collected, FITC-labeled glucocorticoid-induced TNF receptor (ie GITR), and Immunostained with PE-labeled CD4.

Preparation of T _H 1 / T _H 2 cells Peripheral blood mononuclear cells (PBMC) were plated on plates at 2 × 10 ⁶ cells / ml at 37 ° C. for 45 minutes to remove monocytes. Non-adhesive fractions were treated with T _H 1 (IL-2 (4 ng / ml) + IL-12 (5 ng / ml) + Anti-IL-4 (1 μg / ml)) conditions or T _H 2 (IL-2 (4 ng / ml) + IL-4 (4 ng / ml) + anti-IFN-γ (1 μg / ml)) conditions for 3 days Incubated in the presence or absence. Cells were washed and then restimulated with PHA (2.5 μg / ml) for an additional 24 or 48 hours, and then the levels of IFN-γ and IL-4 in the culture supernatant were determined by ELISA (R & D Systems, Minneapolis, Minnesota ).

Analysis of levels of VEGF, PGE ₂ and pro-MMP-1 in MSC culture supernatant Using human MSCs already characterized, interleukin-6 (IL-6), VEGF, lipid mediator prostagland Cultivation of MSCs cultured for 24 hours in the presence or absence of PBMC (MSC to PBMC ratio 1:10) with levels of gin E ₂ (PGE ₂ ) and matrix metalloproteinase 1 (pro-MMP-1) The supernatant was analyzed.

Purified PBMCs were prepared by centrifuging leukopack (Cambrex, Walkersville, Maryland) on PBMC growth Ficoll-Hypaque (Lymphoprep, Oslo, Norway). Dissociated cells in the presence or absence of MSC (precipitated on plates 3-4 hours prior to PBMC addition) in the presence of mitogen PHA (Sigma Chemicals, St. Louis, Missouri) Cultured for 48 hours (triple measurement). In selected experiments, PBMC were resuspended in media containing PGE ₂ inhibitors indomethacin (Sigma Chemicals, St. Louis, Missouri) or NS-938 (Cayman Chemicals, Ann Arbor, Michigan). ( ³ H) thymidine was added (20 μl in a 200 μl culture), and the cells were harvested using an automatic harvester after further incubation for 24 hours. The effect of MSC or PGE ₂ blocker was calculated as a percentage of the control response (100%) in the presence of PHA.

Quantitative RT-PCR
Total RNA was prepared from cell pellets using a commercial kit (Qiagen, Valencia, California) according to the manufacturer's instructions. Contaminating genomic DNA was removed using a DNA free kit (Ambion, Austin, Texas). Quantitative RT-PCR was performed in the MJ Research Opticon detection system (South San Francisco, California) using the QuantiTect SYBR Green RT-PCR kit (Qiagen, Valencia, California) with primers at 0.5 μM concentration. . The relative change in expression level in cells cultured at different conditions was calculated by the difference in Ct values (crossing points) using β-actin as an internal control. The sequences of the COX-1 and COX-2 specific primers were as follows: COX-1: 5′-CCG GAT GCC AGT CAG GAT GAT G-3 ′ (forward), 5′-CTA GAC AGC CAG ATG CTG ACA G-3 '(reverse); COX-2: 5'-ATC TAC CCT CCT CAA GTC CC-3' (forward), 5'-TAC CAG AAG GGC AGG ATA CAG-3 '(reverse).

Increasing numbers of allogeneic PBMCs were incubated with a constant number of MSCs (2,000 cells / well) seeded on 96-well plates in the presence of PHA (2.5 μg / ml) for 72 hours, and ³ H Thymidine incorporation (counts per minute, cpm) was measured. PBMC and MSC were cultured in ratios of 1: 1, 1: 3, 1:10, 1:30, and 1:81 of MSC: PBMC.

Results In this study, the interaction of human MSCs with isolated immune cell populations including dendritic cells (DC1 and DC2), effector T cells (T _H 1 and T _H 2) and NK cells was examined. The interaction of MSCs with each immune cell type had specific results, suggesting that MSCs regulate several steps of the immune response process. Prostaglandin synthesis was suggested by modulating the MSC immunomodulatory action and evaluating the production of secreted factors that may be responsible for this.

By immunomagnetic classification of BDCA1 ⁺ and BDCA2 ⁺ cells, respectively, myeloid (DC1) and plasmacytotic (DC2) precursor dendritic cells were isolated, and for DC1 cells, GM-CSF and IL-4 (1 × 10 ³ each) IU / ml and 1 × 10 ³ IU / ml) and DC2 cells were matured by incubation with IL-3 (10 ng / ml). Using flow cytometry, DC1 cells were HLA-DR ⁺ while DC2 cells were HLA-DR ⁺ and CD123 ⁺ (FIG. 1A). In the presence of the inflammatory agent bacterial lipopolysaccharide (LPS, 1 ng / ml), DC1 cells produced moderate levels of TNF-α, but when MSC was present (ratio 1: 1 and 1:10 examined). ) Had a> 50% reduction in TNF-α secretion (FIG. 1B). On the other hand, DC2 cells produced IL-10 in the presence of LPS, and the level increased more than 2-fold in MSC: DC2 co-culture (1: 1) (FIG. 1B). MSC thus modified the cytokine profile of activated DCs in culture to a more tolerogenic phenotype. Furthermore, activated DCs can reduce IFN-γ and increase IL-4 levels secreted by untreated CD4 ⁺ T cells when cultured with MSC (FIG. 1C), from pro-inflammatory to anti-inflammatory. Suggested MSC sex shift to T cell phenotype.

Since elevated IL-10 secretion plays a role in the generation of regulatory cells (Kingsley, et al., J. Immunol. , Vol. 168, pg. 1080 (2002)), T regulatory cells (T _Reg ) are PBMCs. And quantified by flow cytometry in co-culture with MSC. When PBMC and MSC were cultured for 3-5 days, the number of T _Reg cells measured by staining PBMC with anti-CD4 and anti-CD25 antibodies increased (FIG. 2A), indicating an MSC-induced tolerogenic response. Further support. The CD4 ⁺ CD25 ⁺ T _Reg cell population generated in the presence of MSCs exhibits elevated levels of glucocorticoid-induced TNF receptor (GITR) (a cell surface receptor expressed on the T _Reg cell population) In FIG. 3A and 3B, the allogeneic T cell proliferation was suppressed. MSCs were then examined for their direct ability to affect T cell differentiation. Using purified T cells selected with antibodies (CD4 ⁺ Th cells), IFN-γ producing T _H 1 cells and IL-4 producing T _H 2 cells were generated in the presence or absence of MSC. When MSCs were present during differentiation, IFN-γ secretion by T _H 1 cells decreased and IL-4 secretion by T _H 2 cells increased (FIG. 2B). There was no significant change in IFN-γ and IL-4 levels when MSCs were added to cultures after T cells differentiated into effector T _H 1 or T _H type 2 (data not shown) (day 3) It was. These experiments suggest that MSCs directly affect effector T cell differentiation and change T cell cytokine secretion to a humoral phenotype.

  Similarly, when MSCs are cultured with purified NK cells (CD3-, CD14-, CD19-, CD36-) at different ratios (0 to 48 hours), IFN-γ secretion decreases in the culture supernatant. (FIG. 2C), thus suggesting that MSCs can also regulate NK cell function.

Previous studies have shown that MSCs modify T cell function by soluble factors (LeBlanc, et al., Exp. Hematol. , Vol. 31, pg. 890 (2003); Tse, et al., Transplantation , Vol. 75, pg. 389 (2003)). MSC constitutively secreted several factors including IL-6, prostaglandin E2, VEGF, and pro-MMP-1, and each level was observed to be increased by culture with PBMC ( FIG. 5). To investigate MSC-derived factors that cause inhibition of TNF-α by DC and increased production of IL-10, the possible role of prostaglandin E2 was examined (which inhibits TNF-α production by activated DC (Vassiliou, et al., Cell. Immunol. , Vol. 223, pg. 120 (2003)). Conditioned media from MSC cultures (0.5 × 10 ⁶ cells / ml 24-hour culture) contained approximately 1000 pg / ml PGE ₂ (FIG. 4A). There is no detectable presence of known inducers of PGE ₂ secretion in the culture supernatant, eg, TNF-α, IFN-γ, or IL-1β (data not shown) and the constitutive nature of PGE ₂ by MSC Shows secretion. PGE ₂ secretion by hMSC was inhibited 60-90% in the presence of known inhibitors of PGE ₂ production [NS-398 (5 μM) and indomethacin (4 μM)] (FIG. 4A). Release of PGE ₂ secretion occurs as a result of the enzymatic activity of constitutively active cyclooxygenase enzyme 1 (COX-1) and inducible cyclooxygenase enzyme 2 (COX-2) (Harris, et al., Trends Immunol. , Vol. 23, pg. 144 (2002)), COX-1 and COX-2 mRNA expression in MSC and PBMC was analyzed using a transwell culture system. MSCs express significantly higher levels of COX-2 compared to PBMCs, with increased expression levels> 3 fold when co-cultured with MSC and PBMC (ratio of MSC to PBMC is 1:10) for 24 hours. (FIG. 4B). A slight change was seen in COX-1 levels, suggesting that the increase in PGE ₂ secretion in MSC-PBMC co-cultures (FIG. 5) is mediated by COX-2 upregulation. To immunomodulatory effects of MSC to DC and T cells To determine whether mediated by PGE _2, MSC activated dendritic cells in the presence of NS-398 or indomethacin is PGE ₂ inhibitor (DC1) or T Cultured with _H1 cells. The presence of NS-398 or indomethacin increased TNF-α secretion by DC1 and IFN-γ secretion by T _H 1 cells, respectively (FIG. 4C), and the effect of MSC on immune cell types was due to secreted PGE ₂ Suggested to be mediated. Recent studies have demonstrated that MSC inhibits T cell proliferation induced by various stimuli (DeNicola, et al., Blood , Vol. 99, pg. 3838 (2002); LeBlanc, et al , Scand. J. Immunol. , Vol. 57, pg. 11 (2003)). MSC dose-dependently inhibits mitogen-induced T cell proliferation (FIG. 6), compared to the inhibitor-free control in the presence of the PGE ₂ inhibitors NS-398 (5 μM) or indomethacin (4 μM). Thus, it was observed that ( ³ H) thymidine incorporation was increased by> 70% by PHA-treated PBMC in MSCs containing cultures (FIG. 4D).

In summary, a model for the interaction of MSCs with other immune cell types (FIG. 7) is proposed. In the presence of mature T cells, MSCs interact directly with them, inhibit pro-inflammatory IFN-γ production (path 1), increase the regulatory T cell phenotype (path 3), and anti-inflammatory T _H 2 Increase cells (path 5). Furthermore, MSCs secrete PGE ₂ , inhibit pro-inflammatory DC1 cells (path 2), and increase anti-inflammatory DC 2 cells (path 4) or regulatory DC (path 3), The outcome of a T cell immune response via DC can be altered. The shift to T _H 2 immunity suggests a change in B cell activity towards increased production of IgE / IgG1 subtype antibodies (pathway 7). MSCs appear to modify NK cell function by the ability to inhibit IFN-γ secretion from NK cells (pathway 6). This model of MSC: immune cell interaction is consistent with experiments performed in several other laboratories (LeBlanc, et al., Exp. Hematol. , Vol. 31, pg. 890 (2003); Tse , et al., Transplantation , Vol. 75, pg. 389 (2003); DiNicola, et al., Blood , Vol. 99, pg. 3838 (2002)). Further studies of the proposed mechanism are ongoing and animal studies are needed to investigate the in vivo effects of MSC administration.

Example 2

  Mesenchymal stem cells were administered to a 33 year old female patient suffering from severe stage IV gastrointestinal graft-versus-host disease (GVHD). This patient was resistant to all other GVHD treatments. Endoscopic observation of the patient's colon showed sites of ulceration and inflammation prior to treatment. A histological examination of the patient's colon demonstrated that GVHD had destroyed most of the patient's intestinal crypts prior to treatment.

The patient received an intravenous infusion of allogeneic mesenchymal stem cells in 50 ml of Plasma Lyte A in an amount of 3 × 10 ⁶ cells per kg body weight.

  Patients were evaluated 2 weeks after infusion. At 2 weeks after injection, endoscopic observation of the patient's colon showed that the inflammatory sites and ulceration that had been seen before treatment had disappeared. In addition, a biopsy of the patient's colon showed significant regeneration of the intestinal crypt. That is, administration of mesenchymal stem cells to patients resulted in a significant reduction in the inflammatory component of gastrointestinal graft versus host disease and the regeneration of new functional small intestinal tissue.

  All patents, publications (including published patent applications, deposit accession numbers, and database accession numbers) are all patents, publications (including published patent applications, deposit acceptance numbers, and database accession numbers) Are incorporated herein by reference to the same extent as is specifically and individually incorporated.

However, it should be understood that the scope of the invention is not limited to the specific examples described herein. The present invention may be practiced otherwise than as specifically described herein, and is still within the scope of the appended claims.
Aspect [1] A method for promoting angiogenesis in an organ or tissue of an animal other than the heart,
Said method comprising administering to said animal mesenchymal stem cells in an amount effective to promote angiogenesis in an organ or tissue other than said animal's heart.
[2] The method according to [1], wherein the animal is a mammal.
[3] The method according to [2], wherein the animal is a primate.
[4] The method according to [3], wherein the primate is a human.
[5] The method of [1], wherein the mesenchymal stem cells are administered in an amount of about 1 × 10 ⁵ cells / kg to about 1 × 10 ⁷ cells / kg.
[6] The mesenchymal stem cells are administered in an amount of about 1 × 10 ⁶ cells / kg to about 5 × 10 ⁶ cells / kg, [5] The method according.
[7] The method of [1], wherein the mesenchymal stem cells are administered systemically.
[8] The method according to [1], wherein the mesenchymal stem cells are administered intravenously.
[9] The method according to [1], wherein the mesenchymal stem cells are administered by direct injection into an organ or tissue other than the heart of the animal.
[10] A method of treating a disease selected from the group consisting of an animal autoimmune disease and a graft-versus-host response, comprising the following steps:
Administering to the animal mesenchymal stem cells in an amount effective to treat the disease in the animal;
Said method.
[11] The method according to [10], wherein the animal is a mammal.
[12] The method according to [11], wherein the mammal is a human.
[13] The method according to [10], wherein the disease is multiple sclerosis.
[14] A method for treating an inflammatory response in an animal, comprising administering to the animal an amount of mesenchymal stem cells effective to treat the inflammatory response in the animal.
[15] The method according to [14], wherein the animal is a mammal.
[16] The method according to [15], wherein the mammal is a human.
[17] The method of [14], wherein the inflammatory response is associated with psoriasis.
[18] A method for treating cancer in an animal, comprising administering to the animal an amount of mesenchymal stem cells effective for treating cancer in the animal.
[19] The method according to [18], wherein the animal is a mammal.
[20] The method of [19], wherein the mammal is a human.
[21] A method for treating an allergic disease or disorder in an animal, comprising administering to the animal mesenchymal stem cells in an amount effective for treating the allergic disease or disorder in the animal.
[22] The method according to [21], wherein the animal is a mammal.
[23] The method of [22], wherein the mammal is a human.
[24] The method according to [14], wherein the allergic disease or disorder is arthritis.
[25] A method for promoting wound healing of an animal, comprising administering to the animal mesenchymal stem cells in an amount effective for promoting wound healing of the animal.
[26] The method according to [25], wherein the animal is a mammal.
[27] The method of [26], wherein the mammal is a human.
[28] A method for preventing fibrosis in an animal, comprising administering to the animal mesenchymal stem cells in an amount effective for preventing fibrosis in the animal.
[29] A method for repairing an epithelial injury in an animal, comprising administering to the animal an amount of mesenchymal stem cells effective to repair the epithelial injury in the animal.
[30] The method according to [29], wherein the animal is a mammal.
[31] The method of [30], wherein the mammal is a human.
[32] The method of [29], wherein the epithelial injury is a result of graft-versus-host disease.

FIG. 1A shows that MSC regulates dendritic cell function. Flow cytometric analysis of mature monocyte DC1 cells using antibodies against HLA-DR and CD11c, and flow cytometry analysis of plasmacytoid DC2 cells using antibodies against HLA-DR and CD123 (IL-3 receptor). (Dashed line): isotype control; (solid line): FITC / PE-conjugated antibody. FIG. 1B shows that MSCs inhibit TNF-α secretion (first y-axis) and increase IL-10 secretion (second y-axis) from activated DC1 and DC2, respectively. FIG. 1C shows that MSCs cultured in mature DC1 cells inhibit IFN-γ secretion by T cells (first y axis) and increase IL-4 levels (second y axis) compared to MSC or DC alone. It shows that. Decreased production of pro-inflammatory IFN-γ and increased production of anti-inflammatory IL-4 in the presence of MSC indicated a shift of the T cell population to an anti-inflammatory phenotype. FIG. 2A shows that MSCs inhibit pro-inflammatory effector T cell function. Flow site of T _Reg cell number (%) by staining PBMC or non-adherent fraction in MSC + PBMC cultures (MSC + PBMC) using FITC-conjugated CD4 (x-axis) and PE-conjugated CD25 (y-axis) antibodies Metric analysis. The gate is based on the isotype control antibody as background. The graph is representative of 5 independent experiments. FIG. 2B shows that in cell culture supernatant, T _H 1 cells generated in the presence of MSC secrete low levels of IFN-γ (first y axis), and T _H 2 cells generated in the presence of MSC It shows that an increased amount of IL-4 (second y-axis) was secreted. FIG. 2C shows that MSCs inhibit IFN-γ secretion from purified NK cells cultured in 24-well plates for 0, 24, or 48 hours. Data shown is the mean ± SD cytokine secretion of one experiment and is representative of three independent experiments. FIG. 3A shows that MSC increases the number of T _reg cell populations and GITR expression. CD4 ⁺ CD25 ⁺ T _reg cell populations were isolated from PBMC or MSC + PBMC (MSC to PBMC ratio 1:10) cultures (cultured for 3 days without further stimulation) using a two-step magnetic isolation method. These cells are irradiated (to prevent further proliferation) and used as stimulator cells in a mixed lymphocyte reaction (MLR), where the responder cells are plant hemagglutinin (PHA) (2.5 mg / ml) Allogeneic PBMC in the presence of (stimulating cell to responding cell ratio 1: 100). The cells were cultured for 48 hours, then ³ H thymidine was added and 24 hours later, the incorporated radioactivity was counted. The results showed that the T _reg population generated in the presence of MSC (lane 3) is functionally equivalent to Treg cells generated in the absence of MSC (lane 2). FIG. 3B shows that PBMCs were cultured for 3 days (MSC to PBMC ratio 1:10) in the absence (upper plot) or presence (lower plot) of MSC, and then the non-adherent fraction was collected, The results of immunostaining with FITC-labeled GITR and PE-labeled CD4 are shown. The results show more than a 2-fold increase in GITR expression in cells cultured in the presence of MSC. Figure 4A, MSC is a PGE ₂ produced, indicating that the MSC immunomodulatory effects when blocking PGE ₂ is reversed. PGE ₂ secretion (mean ± SD) in culture supernatants obtained from MSCs cultured in the presence or absence of various concentrations of PGE ₂ blockers NS-398 or indomethacin (Indometh.). The inhibitor concentration is μM, and the data shown are values obtained after 24 hours of culture. FIG. 4B shows COX-1 and COX-2 expression in MSC and PBMC using real-time RT-PCR. MSCs expressed significantly higher levels of COX-2 compared to PBMC, and when MSCs were cultured in the presence of PBMC, there was a more than 3-fold increase in COX-2 expression in MSCs. Representative data from 1-3 independent experiments are shown. MSC + PBMC cultures were prepared in transwell chamber plates, where MSCs were seeded in the lower chamber and PBMCs were seeded in the upper chamber. FIG. 4C shows that (C) the presence of PGE ₂ blockers indomethacin (Ind.) Or NS-398 shows TNF-α secretion from activated DCs (white bars) and T _H 1 cells compared to controls. Shows increased IFN-γ secretion from (hatched bars). Data were calculated as% change from cultures produced in the absence of MSC and PGE ₂ inhibitor. FIG. 4D shows that the presence of PGE ₂ blockers indomethacin (Indo) or NS-398 in MSC-PBMC co-cultures (1:10) reverses MSC anti-proliferative effects on PHA-treated PBMC. The data shown is from one experiment and is representative of three independent experiments. FIG. 5 shows that constitutive MSC cytokine secretion is elevated in the presence of allogeneic PBMC. Cytokines in the culture supernatant of MSCs cultured for 24 hours in the presence (hatched bars) or absence (white bars) (MSC to PBMC ratio 1:10) using human MSCs already characterized IL-6 and VEGF, were analyzed the levels of lipid mediators PGE _2, and matrix metalloproteinase 1 (pro-MMP-1) . The MSC IL-6, VEGF, and produce PGE ₂ constitutively, elevated levels of these factors in the co-culture with PBMC, therefore the MSC to play a role in the regulation of immune function in inflammatory conditions Suggest. FIG. 6 shows that MSCs inhibit mitogen-induced T cell proliferation in a dose-dependent manner. Increasing numbers of allogeneic PBMCs were incubated with a fixed number of MSCs (2,000 cells / well) seeded in 96-well plates in the presence or absence of PHA (2.5 mg / ml), and ³ H Thymidine incorporation was measured (counts per minute, cpm). There was a dose-dependent inhibition of proliferation of PHA-treated PBMC in the presence of MSC. A typical result from one of three independent experiments is shown. Similar results were reported by LeBlanc, et al., Scand J. Immunol., Vol. 57, pg. 11 (2003). FIG. 7 shows a schematic diagram of the proposed MSC mechanism of action. MSCs exert immunomodulatory effects by affecting cells from both the innate (DC pathway 2-4; and NK pathway 6) and adaptive (T pathways 1 and 5, and B pathway 7) immune systems. Mediate. In response to invading pathogens, immature DCs migrate to invading sites, mature, stimulate untreated T cells (by antigen-specific and costimulatory signals), and protective effector T cells (cellular T acquire the ability to become _H 1 or humoral T _H 2 immune). During MSC-DC interactions, MSCs either by direct cell-cell contact or by secreted factors limit the ability of DCs to initiate a cellular response (path 2) or a humoral response (path 4 By altering the outcome of the immune response. Also, when mature effector T cells are present, MSCs interact with them to shift the balance of the T _H 1 (path 1) response towards the TH 2 response (path 5), possibly of IgE-producing B cell activity (path 7). Toward an increase, which is a favorable outcome for the suppression of GvHD and autoimmune disease symptoms. MSCs become a tolerant phenotype by virtue of their ability to increase the generation of the T _Reg population (path 3) and help the recipient host by alleviating bystander inflammation in the local microenvironment. The dotted line is the proposed mechanism.

Claims (33)

  A pharmaceutical composition comprising an effective amount of mesenchymal stem cells for repairing an intestinal crypt in an animal, wherein the mesenchymal stem cell is administered to the animal and promotes an increase in anti-inflammatory cytokine secretion , Pharmaceutical composition.   The pharmaceutical composition according to claim 1, wherein the animal is a mammal.   The pharmaceutical composition according to claim 2, wherein the mammal is a human.   2. The pharmaceutical composition of claim 1, wherein the intestinal crypt is injured as a result of graft-versus-host disease.   The pharmaceutical composition of claim 4, wherein the injured intestinal crypt comprises ulcer intestinal epithelial tissue.   The pharmaceutical composition of claim 1, wherein the animal suffers from graft-versus-host disease.   7. The pharmaceutical composition of claim 6, wherein the graft-versus-host disease is Grade IV gastrointestinal graft-versus-host disease.   The pharmaceutical composition according to claim 1, wherein the administration of the mesenchymal stem cells is provided to the animal only once.   The pharmaceutical composition according to claim 1, wherein the anti-inflammatory cytokine is interleukin-4 (IL-4) and interleukin-10 (IL-10).   8. The pharmaceutical composition according to claim 7, wherein the administration of the mesenchymal stem cells is provided to the animal as a single dose.   11. The pharmaceutical composition of claim 10, wherein the single administration results in regeneration of new functional intestinal tissue.   11. The pharmaceutical composition of claim 10, wherein the single administration eliminates inflammatory sites and ulceration in intestinal tissue.   The pharmaceutical composition according to claim 12, wherein the inflamed site and ulceration in the intestinal tissue disappear within a sufficient time after the injection.   14. The pharmaceutical composition of claim 13, wherein the sufficient time after infusion is at least about 2 weeks. 11. The pharmaceutical composition according to claim 10, wherein the single administration comprises 3 × 10 ⁶ mesenchymal stem cells per kg body weight of the animal.   16. The pharmaceutical composition according to claim 15, wherein the intestinal injury does not recur after administration.   Use of a pharmaceutical composition comprising an effective amount of mesenchymal stem cells for repairing an intestinal crypt in an animal, wherein the composition is administered to the animal and the mesenchymal stem cells are anti-inflammatory cytokines Use to promote increased secretion.   18. Use according to claim 17, wherein the animal is a mammal.   18. Use according to claim 17, wherein the mammal is a human.   18. Use according to claim 17, wherein the intestinal crypt is injured as a result of graft-versus-host disease.   21. Use according to claim 20, wherein the injured intestinal crypt comprises ulcer intestinal epithelial tissue.   18. Use according to claim 17, wherein the animal suffers from graft-versus-host disease.   23. Use according to claim 22, wherein the graft-versus-host disease is grade IV gastrointestinal graft-versus-host disease.   18. Use according to claim 17, wherein the anti-inflammatory cytokines are interleukin-4 (IL-4) and interleukin-10 (IL-10).   18. Use according to claim 17, wherein the administration of the mesenchymal stem cells is provided to the animal only once.   24. Use according to claim 23, wherein the administration of the mesenchymal stem cells is provided to the animal as a single dose.   27. Use according to claim 26, wherein the single administration results in a reduction of the inflammatory component of gastrointestinal graft versus host disease.   24. Use according to claim 23, wherein the single administration results in regeneration of new functional intestinal tissue.   24. Use according to claim 23, wherein the single administration eliminates inflammatory sites and ulceration in intestinal tissue.   30. Use according to claim 29, wherein the site of inflammation and ulceration in the intestinal tissue disappears in a sufficient time after injection.   32. Use according to claim 30, wherein the sufficient time after infusion is at least about 2 weeks. 24. Use according to claim 23, wherein the single dose comprises 3 x 10 < ⁶ > mesenchymal stem cells per kg body weight of the animal.   33. Use according to claim 32, wherein epithelial injury does not recur after administration.